Navigation Links
Alcoholism-associated molecular adaptations in brain neurocognitive circuits
Date:7/8/2008

After many years of heavy drinking, alcohol produces pathological alterations in the brain. In many alcoholics these changes culminate in massive social deterioration and disorders of memory and learning. Severe cognitive impairments occur in approximately 10% of heavy drinkers. Alcoholic dementia is the second leading course of adult dementia in the Western countries, accounting for 10% of the cases, and still represents an unresolved problem. So far no effective pharmacotherapy for memory problems in alcoholics is available.

Nowadays this problem can be approached by innovative research using molecular and epigenetic analyses, which yield new insight into brain pathophysiology. Molecular dysregulations in endogenous opioids a neurotransmitter system in the brain that is central to reward function and pain control are supposed to play a critical role in the development of alcoholism and associated cognitive impairment.

Professor Georgy Bakalkin, involved in a research team focusing on biochemical mechanisms underlying neuropsychiatric disorders, will highlight the latest findings on this clinical challenge and presents a novel mechanism and understanding of cognitive deficit in human alcoholics. Thereby an emerging concept that proposes a new target for pharmacotherapy will be discussed, which might lead to innovative therapeutic interventions to improve or prevent alcohol-induced cognitive impairment in patients with alcohol dependence, and may be generalized to other learning and memory disorders.


'/>"/>

Contact: Sonja Mak
s.mak@update.europe.at
43-140-55734
European College of Neuropsychopharmacology
Source:Eurekalert

Page: 1

Related medicine news :

1. Schizophrenia linked to dysfunction in molecular brain pathway activated by marijuana
2. New research sheds light on the molecular basis of crib death
3. Solis Womens Health Brings Molecular Breast Imaging to Dallas-Fort Worth Metroplex
4. New Molecular Trigger Described for Hypertension, Diabetes
5. New molecular insight into amboebic dysentery
6. Molecular insight begins Trofex Phase 1 trial for detection of metastatic prostate cancer
7. Molecular insight begins Trofex Ph. 1 trial for detection of metastatic prostate cancer
8. Siemens Showcases Innovative Leadership in Molecular Imaging at SNM 2008
9. Xceed Molecular Licenses Signature from Moffitt Cancer Center and Adds Moffitt to Strategic Collaborator Program
10. DiagnoCures molecular diagnostic tests - PCA3 and GCC - discussed at scientific meetings
11. Research reveals molecular fingerprint of cocaine addiction

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...ising incidence of obesity could counter recent in... 2 (HealthDay News) -- The overall health of the U...cades, largely because people have quit smoking in...t soon be wiped out if the rising obesity rates am...rent trends in both smoking and obesity continue u...
(Date:12/2/2009)...hes now available, many more to come, NIH director... News) -- Thirteen stem cell lines have been adde...-funded research, and many more such lines will so...ced Wednesday. , These are the first additional...unded by the U.S. National Institutes of Health (N...
(Date:12/2/2009)...WHITE PLAINS, N.Y., Dec. 2 /PRNewswire-USNewswire/... their findings in blood cancer research at the an...ce in New Orleans December 4-8, 2009. ,, Throu...oma Society (LLS) experts, including Chief Medical...esident of Patient Services Hildy Dillon, and Vice...
(Date:12/2/2009)...PHILADELPHIA, Dec. 2 Independence ...nefits contract with Lincoln Financial Group. IBC ...or approximately 10,000 Lincoln Financial Group em... nation. The Lincoln plan offerings will include t...s. ,, "I know I speak for all of us at Independ...
(Date:12/2/2009)...Joseph Balboni loves sports. An avid tennis player...old insurance agent became increasingly frustrated...us, a degenerative eye disorder. Unable to return ... he faced the prospect of a corneal transplant to ... years ago, Balboni discovered an alternative trea...
Breaking Medicine News(10 mins):Health News:Health Gains From Lowered Smoking Rates in Jeopardy 2Health News:Health Gains From Lowered Smoking Rates in Jeopardy 3Health News:U.S. Approves New Stem Cell Lines for Publicly Funded Research 2Health News:U.S. Approves New Stem Cell Lines for Publicly Funded Research 3Health News:Independence Blue Cross Secures All-Blue Contract with Lincoln Financial Group 2Health News:Independence Blue Cross Secures All-Blue Contract with Lincoln Financial Group 3Health News:Brandeis studies evaluate visionary approach to improving eyesight 2
... Infections during the first year of life are a ma...s of arthritis later in life, according to new res...he Annual Congress of the European League Against ...irst birthday had an increased likelihood of devel...
...he issue of selling kidneys. , A regulated system...tion to the growing shortage of kidneys for transp...ry at the University of Minnesota. , In many are...is the annual death rate for suitable transplant c...
...pedics, Inc., a,leader in orthopedic extremity imp...ecutives, William F. Warrender, Jr., John F. Walte...s. Their extensive background and,experience will ...les. He brings more than 25 years of sales, market...
...Certain single nucleotide polymorphisms (SNPs) wit...region are shown to be associated with juvenile id... of two independent cohorts presented today at EUL... genetic code), rs2104286, rs41295061 and rs115946...
... WASHINGTON, June 13 A team of professionals,fro...to Germany on Saturday,to work with the US Army,s ...ng their current rehabilitation practices. They wi...tation,services. The ERMC operates 15 ambulatory c...
... try to resolve remaining issues, TORONTO, June 1...pany,PreMD Inc. (TSX: PMD; Amex: PME) today announ... the U.S. Food and Drug Administration (FDA) in an...next 60 days PreMD and the FDA will work together ...
Other Medicine News:Health News:Early life infections increase the risk of rheumatoid arthritis and juvenile idiopathic arthritis 2Health News:What's wrong with selling kidneys? 2Health News:Three Industry Veterans Join Ascension Orthopedics 2Health News:Three Industry Veterans Join Ascension Orthopedics 3Health News:Specific mutations in the IL2RA gene associated with juvenile idiopathic arthritis 2Health News:National Rehabilitation Hospital Team to Work with US Army to Improve Rehab Care for Wounded Soldiers 2Health News:National Rehabilitation Hospital Team to Work with US Army to Improve Rehab Care for Wounded Soldiers 3Health News:National Rehabilitation Hospital Team to Work with US Army to Improve Rehab Care for Wounded Soldiers 4Health News:National Rehabilitation Hospital Team to Work with US Army to Improve Rehab Care for Wounded Soldiers 5Health News:PreMD Reports Further Positive Meetings with the FDA 2
(Date:12/2/2009)...NEW YORK, Dec. 2 Keryx B...ounced that the U.S. Food and Drug Administration ...401 (perifosine), the Company,s novel, potentially...its the phosphoinositide 3-kinase (PI3K)/Akt pathw...ple myeloma. ,, The Fast Track program of the...
(Date:12/2/2009)... NANJING, China, Dec. 2 /PRNewswire-Asia/ -- S...pany") (NYSE: SCR ), a leading pharmaceutical co...ng, and marketing of branded,generic and proprieta...ts,subsidiary Jiangsu Yanshen Biological Technolog...d production of all its products in order to condu...
(Date:12/1/2009)..., NEW YORK, Dec . 1 Reportlinker.... available in its catalogue: ,, Insulin Pumps ...www.reportlinker.com/p0164247/Insulin-Pumps-Extern...ps, also called Continuous Subcutaneous Insulin In...s, when compared to other forms of treatment. Insu...
Breaking Medicine Technology:Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma 2Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma 3Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma 4Simcere Pharmaceutical Group Announces Jiangsu Yanshen's Voluntary Suspension of Production 2Simcere Pharmaceutical Group Announces Jiangsu Yanshen's Voluntary Suspension of Production 3Reportlinker Adds Insulin Pumps (External) - A World Market Review 2Reportlinker Adds Insulin Pumps (External) - A World Market Review 3Reportlinker Adds Insulin Pumps (External) - A World Market Review 4Recovery Audit Contractor Connolly Healthcare Licenses Milliman Care Guidelines 28R 29 47886 1Recovery Audit Contractor Connolly Healthcare Licenses Milliman Care Guidelines 28R 29 47886 2Recovery Audit Contractor Connolly Healthcare Licenses Milliman Care Guidelines 28R 29 47886 3Go Healthy Enters Letter of Intent to Acquire Premium Water Source 47883 1Go Healthy Enters Letter of Intent to Acquire Premium Water Source 47883 2Xanodyne Announces New President CEO and Completes 2438 Million Equity Financing 47880 1Xanodyne Announces New President CEO and Completes 2438 Million Equity Financing 47880 2
...spimycin is Industry,s First Hsp90 Inhibitor to En...ogram TIME Registration Program Utilizes New, P... Formulation, HAYWARD, Calif., Aug. 2 Kosan Bi...unced that the TIME-2 trial is open,and enrolling ...imycin in,Myeloma Evaluation or "TIME" registratio...
...cess to Large Population of Glioblastoma Patients ...ll Study of Promising New Approach -, TUSTIN, Cal...aq: PPHM ), a clinical stage biopharmaceutical,co...r the treatment of,cancer and hepatitis C virus in...s been administered Cotara(R) in a new clinical tr...
Other Medicine Technology:Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma 2Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma 3Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma 4Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma 5Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma 6Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India 2Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India 3Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India 4
Right Dr. White Carina Hook
SHERIDAN LASER-TRACH Endotracheal Tubes
SHERIDAN LAR-A-JECT® Reinforced Laryngectomy Tubes
SPIRAL-FLEX® Reinforced Oral/Nasal Cuffed Endotracheal Tubes
Medicine Products: